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Abstract
Vertebrate organisms adapt to a continuously changing environment by regulating the
strength of synaptic connections between brain cells. Excitatory synapses are believed to
increase their strength by vesicular insertion of transmitter glutamate receptors into the
postsynaptic plasma membrane. These vesicles, however, have never been demonstrated
or characterized. For the first time, we show the presence of small vesicles in postsynaptic
spines, often closely adjacent to the plasma membrane and PSD (postsynaptic density).
We demonstrate that they harbor vesicle-associated membrane protein 2 (VAMP2/synapto-
brevin-2) and glutamate receptor subunit 1 (GluA1). Disrupting VAMP2 by tetanus toxin
treatment reduces the concentration of GluA1 in the postsynaptic plasma membrane.
GluA1/VAMP2-containing vesicles, but not GluA2/VAMP2-vesicles, are concentrated in
postsynaptic spines relative to dendrites. Our results indicate that small postsynaptic vesi-
cles containing GluA1 are inserted directly into the spine plasma membrane through a
VAMP2-dependent mechanism.
Introduction
Synapses are junctions between neurons where the flow of information in the brain can be
modified [1]. The most widely used excitatory neurotransmitter is the amino acid glutamate
[2]. Glutamate receptors of the AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid) class are tetramers of different subunits (GluA1-4) [3].
Synaptic plasticity, through changes in the postsynaptic plasma membrane concentration of
the AMPA receptors, enables the organism to adapt to changes in the environment [4, 5]. The
receptors, or their subunits, recycle between cytoplasmic and membrane pools [6]. This cycling
may allow fast, regulated changes in synaptic AMPA receptor concentration, thus enabling
changes in synaptic strength [7]. Indirect evidence indicates a vesicular mechanism for this
recycling [8]. To our knowledge, no previous investigations have directly demonstrated the
presence of such receptor-containing postsynaptic vesicles.
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One of the last steps in the transport of glutamate receptors to the synapse is their delivery
into the specialized dendritic membrane of the spine postsynaptic density (PSD). The exocyto-
sis of receptors is required for long-term potentiation (LTP) [9–11], in addition to the constitu-
tive insertion of new receptors in basal conditions [9]. Receptors can be either directly inserted
into the synapse, or into the extra-synaptic membrane, followed by their lateral diffusion and
subsequent trapping at synaptic sites. Regulated insertion of AMPA receptors may be initiated
by NMDA (N-methyl-D-aspartate) receptor activation [12]. Though receptors are probably
assembled prior to their transport to the synapses, we do not know whether the receptors may
also be modified locally by single subunit trafficking to the postsynaptic plasma membrane for
assembly there.
AMPA receptors are most likely synthesized as monomers in the endoplasmic reticulum,
before subsequent insertion into the endoplasmic reticular membrane. Here they assemble dif-
ferentially into dimers of dimers, i.e. tetramers [13, 14]. Tetrameric AMPA receptors then con-
tinue to the Golgi apparatus and exit the trans-Golgi network with trafficking vesicles. Some
investigations, however, point to the possibility of differential trafficking of GluA1- and
GluA2-containing receptors [15, 16]. GluA1 and GluA2 subunits can also be synthesized in
dendrites in an activity-dependent or an activity-independent manner [17].
Exocytosis in neurons requires proteins known as Soluble NSF Attachment Protein Recep-
tors (SNAREs), membrane proteins that are involved in many intracellular fusion events.
According to the SNARE hypothesis, membrane fusion results from the interaction of specific
vesicle and target SNAREs that bring their respective membranes into close opposition leading
to fusion [18]. An important step in these processes is the assembly of a complex consisting of
a small number of proteins, forming the core SNARE complex. In nerve terminals, this com-
plex consists of VAMP2/synaptobrevin-2, which resides at presynaptic vesicle membranes, and
syntaxin-1 and SNAP-25 at the corresponding presynaptic plasma membrane [19].
In addition to their crucial role in presynaptic exocytosis [19–22], SNARE proteins are main
candidates for a regulatory role in the fusion of receptor-containing organelles with the post-
synaptic plasma membrane [10, 23–26]. VAMP is a small integral membrane protein of synap-
tic vesicles in vertebrates and invertebrates. The protein is highly conserved across evolution.
VAMP1 and VAMP2 are brain-specific and expressed in a non-overlapping pattern, though
VAMP2 is much more ubiquitous then VAMP1 in the CNS [27].
We wanted to determine whether the vesicle SNARE VAMP2 is present in postsynaptic
spines in the brain, whether it is associated with postsynaptic vesicles containing AMPA recep-
tor subunits, and if it contributes to the exocytotic insertion of these AMPA receptor subunits
into the plasma membrane.
Material and Methods
The crucial technology that facilitated these observations was immunogold postembedding
electron microscopy with antibodies against glutaraldehyde-fixed antigen [28], in combination
with freeze-substituted brain tissue fixed with formaldehyde and very low concentrations of
glutaraldehyde, without osmium treatment [29]. The freeze-substitution technique has proven
effective in visualizing synaptic-like microvesicles in other sites than presynaptic terminals [30,
31].
Antibodies
Anti-VAMP2 was raised in rabbit immunized with recombinant VAMP2/synaptobrevin [32]
protein (amino acid 1–96, 15% identical with VAMP1 amino acid 1–96) fixed in 1.25% glutar-
aldehyde and mixed with Freund’s adjuvant. The VAMP2 construct (pGEX-KG vector) was a
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generous gift from Richard Scheller. Crude antiserum was affinity-purified with recombinant
VAMP2 protein (affi-gel column). Anti-VAMP2 was used at 1:10,000–50,000 for western blot-
ting, 1:10–1:50 for postembedding electron microscopy (EM), 1:100 for immunofluorescence
confocal microscopy and 5–10 μg/50 μl beads for immunoprecipitation. Anti-GluA1 (GluR1)
(Alomone Labs, Jerusalem, Israel, Cat#AGC-004) was used at 1:500 for immunofluorescence.
Anti-GluA1 (GluR1) (Millipore, MA, USA, Cat#AB1504) was used at 1:20 for electron micros-
copy and at 5–10 μg/50 μl beads for immunoprecipitation. Anti-GluA1 (GluR1) (Upstate, NY,
USA, Cat#07–660) was used at 1:1000 for western blotting. Anti-GluA2 (GluR2) (Alomone
Labs, Jerusalem, Israel, Cat#AGC-005) was used at 1:500 for immunofluorescence, 1:25 for
electron microscopy, 1:1000 for WB and 5–10 μg/50 μl beads for immunoprecipitation. Anti-
synaptophysin (Millipore, MA, USA, Cat#MAB368) was used at 1:50,000 for western blotting
and at 1:200 for immunofluoroscence. Anti-PSD95 (Novus Biological, CO, USA, Cat#NB300-
556) was used at 1:75 for immunofluorescence. Anti-phosphate-activated glutaminase [33] (in-
house) was used at 1:150,000 for western blotting. Anti-ß-tubulin (Tuj1) (Covance, CA, USA,
MMS-435P) was used at 1:100 for immunofluorescence and 1:10,000 for western blotting. Sec-
ondary antibodies: Donkey anti-rabbit Cy3 (Jackson Immuno, MD, USA, Cat#711-165-152)
and donkey anti-mouse A488 (Invitrogen, CA, USA, Cat#A21202) was used at 1:1000 for
immunofluorescence. Goat anti-rabbit alkaline phosphatase (Sigma, MO, USA, A3687) and
Goat anti-mouse alkaline phosphatase (Sigma, MO, USA, Cat#A3562) was used at 1:10,000 for
western blotting. IgG coupled to 10 or 20 nm colloidal gold (Abcam, Cambridge, UK,
Cat#ab27234) and (British BioCell International, Cardiff, UK, Cat#R14007) was used at 1:20.
Animals
All animal experimentation was carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC). Formal approval to conduct the experi-
ments described was obtained from the animal subjects review board of the Norwegian Gov-
ernmental Institute of Public Health (Oslo, Norway). Care was taken to minimize the number
of animals used and to avoid suffering. According to established routines in our EM lab, adult
male Wistar rats, 2–4 months, (from Scanbur, Nittedal, Norway), weighing 250–300 g, were
used for EM, and 1–4 day-old Wistar rats for primary hippocampal cultures. Similarly, adult
PVG male rats, 2–4 months, (Scanbur), weighing 200–250 g, were used for western blotting.
VAMP2 knock out mice brains [34] were generously provided by Ege Kavalali, University of
Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Immunocytochemistry
Perfusion fixation. For electron microscopy studies, the rats were deeply anesthetized
with Equithesin (0.4 ml/100 g body weight), followed by intracardiac perfusion with 10–15 s
flush of 4% Dextran-T70 in 0.1 M sodium phosphate buffer (pH 7.4), before perfusion with a
mixture of 4% formaldehyde and 0.1% glutaraldehyde in the same buffer. Time for perfusion
was approximately 15 minutes. The rats were then left overnight ON in a cold room. The next
day, the brains were carefully dissected out and stored in a sodium phosphate buffer (0,1 M
with 0.4% FA and 0,01% GA).
Electron microscopy. Small (0.5–1.0 mm) blocks dissected out from the CA1 area of the
hippocampus were freeze-substituted, sectioned, and immunolabeled essentially as described
previously [29, 35]. For double labeling, the sections were first incubated with either rabbit
polyclonal anti-GluA1 or anti-GluA2 followed by goat anti-rabbit coupled to 20 nm colloidal
gold. The sections were exposed to formaldehyde vapor at 80 C for 1 h and thereafter incubated
with rabbit polyclonal anti-VAMP2, followed by goat anti-rabbit coupled to 10 nm colloidal
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gold. The sections were the contrasted with uranyl acetate and lead citrate and examined with a
Fei Tecnai 12 electron microscope.
Quantification and statistical analysis of immunogold labelling. Electron micrographs
from rats (n = 3) were obtained from asymmetric synapses (Schaffer collateral synapses) from
the middle layer of stratum radiatum of the CA1 region of the hippocampus. VAMP2 immuno-
labeling was quantified as the number of gold particles/μm of membrane length in asymmetric
synapses and as the number of gold particles/μm2 in the intracellular compartment. One hun-
dred eighty profiles from each region of interest were quantified (60 profiles from each rat). Spe-
cific plasma membrane and cytoplasmic compartments were defined and used for
quantifications. The synaptic lateral membranes were defined for convenience of measurement
as equal to the length of the PSD, on both sides of the PSD or AZ, for all synapses. Only synaptic
profiles with clearly visible synaptic membranes and postsynaptic density were selected for quan-
titative analysis. An in-house extension to the analySIS software connected with SPSS (SPSS Inc,
Chicago, IL, USA) was used to quantify the gold particle labeling of the regions of interest. The
software calculated area gold particle density (number per unit area) over cytoplasmic compart-
ments and linear particle density (number per unit length of curve) over membrane domains. In
the latter case, it measured the distance from each particle-center to the membrane, and included
only those particles which were within an operator-defined distance from the curve segment. For
plasma membranes, the inclusion distance was symmetric between -21 nm, and +21 nm (nega-
tive signifying an intracellular location). Data for particles were collected in ASCII files as flat
tables and exported to SPSS for further statistical and graphical analysis.
ImageJ was used to quantify double immunogold labeling. Gold particles located within a
77 nm radius from each other were classified as colocalized. The distance 77 nm was deter-
mined by summarizing the length of 2 x primary antibody (16 nm), length of 2 x secondary
antibody (16 nm), radius of 10 nm gold particle (5 nm), radius of 20 nm gold particle (10 nm)
and diameter of postsynaptic vesicle (30 nm).
For specificity control of VAMP2 immunogold labeling, we quantified gold particle densi-
ties over presynaptic, vesicle-filled cytoplasm in newborn knockout and wild type mouse hip-
pocampi (after immersion fixation in our standard fixative), and in adult wild type rat
hippocampi with and without preincubation of the antibody with identical VAMP2 protein to
that which was used for immunization. The quantified results were analyzed with a Mann-
Whitney test.
Homozygote VAMP2 knock out animals die immediately after birth [34], at a different
developmental stage from the adult rat brains we used, and perfusion fixation of newborn mice
is technically challenging, with a risk of altered perfusion parameters compared to adult rats.
The abundant pool of presynaptic vesicles was used as our region of interest for quantification
in these control experiments.
Immunoisolation of vesicles
GluA1, GluA2 and VAMP2 antibody was coupled to Dynabeads Protein A (Dynal, Oslo, Nor-
way), [36]. Vesicle fractions were incubated with beads overnight under rotation at 4°C. The
flow-through and the beads fraction were separated, rinsed, collected and homogenized in SDS
solubilization buffer (10 mg/ml SDS, 5 mM EDTA and 10 mM sodium phosphate buffer, pH
7.4). The homogenates were run on 14–20% SDS-acrylamide gels. There is no well-established
protocol for distinctly separating pre- and postsynaptic vesicles in a biochemical preparation,
so our samples evidently contained both types. There is no reason to believe, however, that all
VAMP2-positive vesicles contain GluA1, as presynaptic vesicles (with VAMP2) would proba-
bly be low in GluA1 concentrations.
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Preparation of synaptosome and vesicle membrane fractions
Ten rats were decapitated, and the brains were dissected out, and submerged in ice-cold
Hepes-buffered sucrose (0.32 M sucrose, 4 mMHepes, pH 7.4) containing a protease inhibitor
cocktail (0.1 mM PMSF, 1.5 μg/ml ea. aprotin, 10 μg/ml ea. antipain/ leupeptin, 10 μg/ml ea.
chymostatin/pepstatin, 0.1 mg/ml benzamidine) and a phosphatase inhibitor cocktail (2 mM
EGTA, 50 mMNaF, 10 mM sodium pyrophosphate, 20 mM -glycerophosphate, 1 mM para-
nitrophenylphosphate (PNPP), 1 μMmicrocystin LR, 1 mM sodium orthovanadate, 0.1 mM
ammonium molybdate). The tissue was homogenized in a Hepes buffer with a glass-Teflon
homogenizer (900 rpm, 10–15 strokes) and centrifuged (800–1000 μg, 10 min, 4°C). The post-
nuclear supernatant S1 was centrifuged (10,000 g, 15 min), and the pellet containing crude syn-
aptosomes was resuspended in 10 volumes of Hepes-buffered sucrose and centrifuged (10,000
g, 15 min). The synaptosomal fraction was resuspended in 10 mM sucrose, centrifuged
(161,000 g, 25 min); the gradient interphase was collected and diluted in Hepes-buffered
sucrose, and centrifuged again (161,000 g, 25 min) to get a pellet containing pure synapto-
somes. To extract synaptic vesicles, the pure synaptosome pellet was lysed by hypo-osmotic
shock in nine volumes of ice-cold H2O plus protease/phosphatase inhibitors and three strokes
with a glass-Teflon homogenizer; this solution was adjusted to 4 mMHepes and mixed at 4°C
for 30 min to ensure complete lysis. The lysate was centrifuged (161,000 g, 25 min), before the
resulting supernatant again was centrifuged (165,000 g for 2 h) and then resuspended in 50
mMHepes, 2 mM EDTA plus protease/phosphatise inhibitors.
Immunoblotting
The homogenates were run on 4–20% SDS–acrylamide, and then electroblotted onto PVDF
membrane (Hoefer Scientific Instruments, San Francisco, CA, USA) and immunostained with
primary antibodies and horseradish peroxidase-linked secondary antibody (Amersham Biosci-
ences, UK). The signal was detected by fluorescence using ECF substrate (Amersham Biosci-
ences, UK). The fluorescence signals were visualized by a fluorescence digital camera detection
system (Typhoon and Kodak scanner).
Preparation of hippocampal neuronal cultures
Primary hippocampal cultures containing both neurons and glial cells of 1–4 day-old rats
(Wistar) were prepared as previously described [37]. Briefly, cultures were prepared from 1–4
day-old rats. They were maintained in cell medium (Gibcos MEM with the addition of 30 mg/
100 ml glutamine; 2.5 mg/100 ml insulin; 5–10% fetal calf serum; 2 ml/100 ml B 27 and 2–10
micro liter/100 ml ARA-C) in 5% CO2, 95% air incubator at 37°C. The cells were fixed in 2.5%
glutaraldehyde (GA) and 1% formaldehyde (FA) by the following procedure: freshly prepared
fixative (2% FA in 0.1 M sodium phosphate buffer) was heated to 37°C before adding it to the
culture medium (equal volumes). After 30 min this mixture was substituted with 4% FA in 0,1
M sodium phosphate buffer ON. The cells were stored in 0,1 FA in 0,1 M sodium phosphate
buffer.
Treatment of neuron cultures with tetanus toxin and Bafilomycin A1 and
confocal microscopy scanning
Cultures were incubated with 13.3 nM tetanus toxin or 1 μM Bafilomycin A1 in culture
medium overnight (ON) before they were fixed. They were labeled with primary antibody in
2% (v/v) normal calf serum and 1% (w/v) bovine serum albumin and 0.4% saponin in 0.1 M
sodium phosphate buffer at pH 7.4 (ON). Saponin was omitted in GluA1- or GluA2-labeling
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against the extracelluar epitope. The cultures were rinsed in the buffer, incubated for 30 min
with secondary antibodies and rinsed again in the buffer. The cultures were mounted with
fluormont mounting media (Southern Biotech), and examined with an Axioplan 2 equipped
with a LSM 5 Pascal scanner head (Carl Zeiss, Heidelberg, Germany). Tetanus toxin does not
cleave VAMP2 that is already assembled in a SNARE complex [38]. Thus, even after toxin
treatment, there will be some insertion of GluA1 receptor subunits associated with already
docked vesicles.
Quantification and statistical analysis of hippocampal neuronal cultures
Quantification of GluA1 immunofluorescence intensity was performed with LSM image ana-
lyzer software over morphologically identified boutons in both the control and experiment
groups (n = 1000 synapses for the tetanus group, and n = 500 synapses for the Bafilomycin
group). Fluorescence intensities of individual boutons were analyzed in control and tetanus or
Bafilomycin-treated neuronal cultures. The cultures used for quantification were from the
same batch of animals, and were used on the same day. In all cultures, images were taken from
the center of the culture, where the density of synapses was comparatively equal and greatest.
We identified neuronal cell somata and followed the dendrites peripherally. Along these den-
drites, synapses were localized as fluorescent puncta. We used fluorescence intensity as a mea-
sure of glutamate receptor concentration in these synapses. Furthermore, we quantified the
staining intensity of single synapses. The results were independent of the total number of syn-
apses in each culture. LSM image analyzer software was used to generate a histogram of the
intensities along a straight line across individual boutons, and maximum immunofluorescence
intensity from each bouton was obtained. Means were then calculated for the population of
boutons in a given culture. Statistical analyses were performed in SPSS for Windows (SPSS
Inc., Chicago, IL). The quantified results with tetanus toxin treatment were analyzed with inde-
pendent samples T-test. The quantified results with Bafilomycin A1 treatment were analyzed
with a Mann-Whitney test.
Results
Specificity of in-house VAMP2 antibody
Our anti-VAMP2 antibody was characterized at the western blot and electron microscopy lev-
els. First, we used the antibody on western blots of brain homogenate from newborn wild type
and VAMP2 knockout mice [34] (Fig 1A). Immunoblots from wild type mice show one band,
as expected at 18 kDa, while this is not present with the VAMP2 knockout brain homogenate.
This band was also present with rat brain homogenate, and it was further strengthened in syn-
aptosomal and synaptic vesicle fractions, as expected (Fig 1B). In order to specifically test the
antibody at the electron microscopical level, we performed immunogold labeling of hippocam-
pus from newborn VAMP2 knockout mice (Fig 1D4) and wild type mice (Fig 1D3), immersion
fixed with the same fixative as the one used for the rat experiments. Quantification of gold par-
ticle densities over vesicle-filled, presynaptic, hippocampal terminals at the electron micro-
scopical level showed an almost eightfold higher labeling in wild type compared to knockout
animals (n = 20 in both groups, p< 0.001, Mann-Whitney U test) (Fig 1C). We used immer-
sion fixation of newborn VAMP2 knockout mouse hippocampus for this control, as rat
VAMP2 knockout animals were not available, and the mouse knockouts die immediately after
birth. We also labeled adult rat hippocampal terminals at the electron microscopical level with
antibody after pre-incubation with the same antigen used for immunization of the rabbits (Fig
1D2), where control labeling of presynaptic vesicles without pre-incubation (Fig 1D1) was
almost seventeen-fold higher (n = 20 in both groups, p< 0.001, Mann-Whitney U test) (Fig
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1C). These experiments show high specificity and selectivity of our in-house VAMP2 antibody,
also at the electron microscopical level.
VAMP2 expression in the brain
To determine relative concentrations of VAMP2 in different brain regions, we performed
quantitative western blot (Fig 2A–2C). Results from these experiments show that the highest
concentration is found in the hippocampus, the lowest in the spinal cord (Fig 2C). The cortex,
thalamus, brain stem and cerebellum showed almost equal expressions of VAMP2. Staining of
Fig 1. Specificity of in-house VAMP2 antibody. (A) Brain homogenates from wild type (WT1–2) and
knockout (KO1–3) mice. The VAMP2 band at 18kDa is absent from brains of the three knockout mice. Protein
loaded 30 μg. (B) Western blots from wild type rat brain. BH: brain homogenate; S: crude synaptosomes; SV:
synaptic vesicles. Only one band was seen in each preparation. Protein loaded 10 μg. (C) Quantitative
analysis of immunogold labeling with anti-VAMP2 of presynaptic cytoplasm at excitatory synapses in
hippocampus, preincubated with VAMP2 protein. Ultrastructural quantification of VAMP2 immunogold
labeling of presynaptic cytoplasm at excitatory synapses in hippocampus of VAMP2 KOmice. Statistical
significance (p < 0.001). (D) Electron micrographs showing labeling for VAMP2. (D1) Standard labeling, i.e.
normal immunogold without pre-incubation with antigen. (D2) Pre-incubation with VAMP2 antigen. (D3)
Standard labeling of wildtype. (D4) Labeling of VAMP2-KO tissue. Scale bar: 125 nm.
doi:10.1371/journal.pone.0140868.g001
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Fig 2. Regional VAMP2 expression in the rat brain. (A) Staining of homogenates from different brain
regions with anti-VAMP2, i.e. cortex (Cx), thalamus (Th), hippocampus [64], brain stem (Bs), cerebellum
(Cb), and spinal cord (SpC). Protein loaded 7,5 μg. (B) Staining of different brain regions with anti-beta-
tubulin. Protein loaded: 5 μg. (C) Quantitation of intensities of bands seen above, indicating highest
concentration in the hippocampus, lowest in the spinal cord. Fluorescence intensity of anti-VAMP2 staining
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different brain regions with the neuronal marker anti β-tubulin was used as the loading control
for quantitative western blot experiments (Fig 2B). Light microscopy revealed strong immu-
nostaining of VAMP2 in the cerebral cortex, hippocampus, thalamus and cerebellum (Fig
2D1–2D3), similar to what has been shown with mRNA hybridization [27]. At higher magnifi-
cation, somata and proximal dendrites of principal neurons were weakly to moderately immu-
nopositive for VAMP2, but were bordered with characteristic punctate staining, as would be
expected from synapses (Fig 2D4–2D9). The results were in line with published anti-VAMP2
immunostaining.
Ultrastructural localization of VAMP2
In order to determine the localization of VAMP2 within the synapse, we analyzed postembed-
ding immunogold labeling of the protein in Schaffer collateral synapses in ultrathin sections
from the stratum radiatum of the CA1 region in rat hippocampus (Fig 3). Many presynaptic
vesicles were labeled, with gold particles localized either close to the vesicle membrane, or
within the vesicle lumen (Fig 3A). The latter indicated that the secondary antibody-coated gold
particle was attached to more than one VAMP2 epitope along the vesicle membrane. Gold par-
ticles were also accumulated along the presynaptic active zone, probably resulting from vesicles
recently fused with the plasma membrane. Confirming our hypothesis, however, labeling of
postsynaptic spines was also seen. Specifically, both the PSD and scattered postsynaptic vesicles
were labeled with the VAMP2 antibody (Fig 3A and 3B). These vesicles had a mean diameter
of 25 nm, i.e. at the smaller end of the presynaptic vesicle range [26], which in our material had
a mean diameter of 35 nm. The small postsynaptic vesicles were located deeply within the post-
synaptic cytoplasm or adjacent to the plasma membrane, both at the PSD and lateral plasma
membrane. Clusters of a few VAMP2 positive vesicles were often seen at the plasma membrane
close to the PSD (Fig 3A). Again, gold particles were seen both within the vesicle lumen, as well
as on the vesicle membrane. Electron-lucent areas were seen between centrally located gold
particles in the vesicles and the vesicle membrane, showing that the 10 nm gold particles did
not completely fill the space of the lumen.
In conclusion, postsynaptic spines contain organelles that may be capable of trafficking
between cytoplasmic and plasma membrane compartments, i.e. vesicles carrying the SNARE
protein VAMP2. To further confirm synaptic localization of VAMP2, we performed double
immunofluorescence labeling of cultured hippocampal neurons with VAMP2 and synaptic
markers. Immunolabeling showed punctate staining with anti-VAMP2 along neuronal den-
drites (Fig 4A–4C). As expected, VAMP2 colocalized with a presynaptic vesicle marker, synap-
tophysin (Fig 4D–4F), and with a postsynaptic marker, PSD-95 (Fig 4G–4I).
VAMP2 concentration in subregions of the synapse
In order to determine the relative concentration of VAMP2 in different subregions of the syn-
apse, we quantified the mean number of immunogold particles over different cytoplasmic and
membrane regions of interest (Fig 5A). The density of presynaptic VAMP2 peaked at about
was normalized to anti-beta-tubulin staining. (D) Vibratome sections immunostained for VAMP2. Anti-VAMP2
antibody produced immunoperoxidase-staining of neurons in hippocampus, cerebellum, cerebral cortex and
thalamus (D1–D3). In the hippocampus, the somata and proximal dendrites of pyramidal neurons were
strongly stained in sub-regions of CA1 (D4) and CA3 (D5), as were the granule cells in dentate gyrus (D6).
Strong immunostaining was found in purkinje cell somata and the proximal dendrites in the cerebellar cortex
(D9), and in the pyramidal cells of the cerebral cortex (D7). Immunolabeling was also observed in thalamic
neurons (D8). Immunoperoxidase staining. Scale bar: (D1): 1000 μm. (D2): 2000 μm, (D3): 500 μm, (D4–D8):
20 μm, (D9): 50 μm.
doi:10.1371/journal.pone.0140868.g002
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70–140 nm from the active zone (Fig 5B), a subsynaptic region that is dense in vesicles. The
postsynaptic spine cytoplasm density of VAMP2 labeling was about half that of the presynaptic
cytoplasm, but still more than double the density in dendritic cytoplasm (Fig 5C). Plasma
membrane labeling in the presynaptic terminal was concentrated in the active zone, with label-
ing more than double the density found over presynaptic lateral membrane (Fig 5D), as would
be expected for a membrane domain specialized for presynaptic vesicle exocytosis. Postsynapti-
cally, however, there was not a similar difference between synaptic and lateral synaptic plasma
membrane labeling. We observed about the same concentration over the PSD as over the post-
synaptic lateral membrane (Fig 5D), indicating that exocytosis may occur at both these sites.
The density at the PSD-related plasma membrane, however, was markedly higher than at the
dendritic plasma membrane, which again was higher than the astrocytic plasma membrane.
The highest postsynaptic concentrations are clearly found at the PSD or close to it. These
observations indicate that vesicle fusion with the postsynaptic spine plasma membrane may
occur both directly at the synapse as well as in lateral spine areas.
Fig 3. Electron micrographs showing VAMP2 immunogold labeling of vesicles in asymmetric
synapses from the CA1 region of the rat hippocampus. (A) Gold particles are present over pre- and
postsynaptic vesicles (arrowheads), as well as some at synaptic plasmamembranes. Scale bar: 200 nm. (B)
Selected postsynaptic vesicles (arrowheads) in higher magnification. Presynaptic vesicles are also seen.
Synaptic cleft is marked with an asterisk. Scale bar: 75 nm.
doi:10.1371/journal.pone.0140868.g003
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Postsynaptic colocalization of AMPA receptor subunits and VAMP2
We next wanted to explore whether the labeled postsynaptic vesicles harbored AMPA recep-
tors, which would be expected if these vesicles contribute to insertion of AMPA receptors into
the synapse, thus playing a role in synaptic plasticity. Electron microscopical postembedding
immunogold double labeling, for GluA1 and VAMP2, showed that these proteins were often
colocalized over vesicles in postsynaptic spines and in dendritic shafts (Fig 6A). Quantitative
analysis of immunogold double labeling revealed that GluA1 and VAMP2 were clearly more
often colocalized at small vesicles in dendritic spines than in dendritic shafts. Eighty-eight per-
cent of GluA1-gold particles in spines were located close to VAMP2-gold particles, while the
corresponding number for dendritic shafts was only 33% (Fig 6B), indicating that VAMP2-me-
diated vesicular insertion of GluA1 subunits is more common in spines than in dendrites. To
further substantiate that the same vesicles could harbor both proteins, we used magnetic beads
coupled to a GluA1 antibody to immunoprecipitate (IP) AMPA receptor-containing vesicles
from whole rat brain synaptic vesicles. The crude brain homogenate and the synaptic vesicle
preparation were positive for both VAMP2 and GluA1 (Fig 6E, 6F and 6I). Vesicles immuno-
precipitated with the GluA1 beads were positive for GluA1 (Fig 6E), but also for VAMP2 (Fig
6F). Conversely, vesicles immunoprecipitated with anti-VAMP2 beads were positive for
VAMP2 (Fig 6I), but also for GluA1 (Fig 6J).
We performed similar experiments with antibodies to GluA2 and VAMP2. Immunogold
double labeling of excitatory synapses in hippocampus with anti-VAMP2 and anti-GluA2
more rarely showed colocalization of these proteins over vesicles in postsynaptic spines (Fig
Fig 4. Confocal images of dissociated hippocampal cultures.Double labeling with anti-TUJ1 (A) and anti-VAMP2 (B) demonstrates that VAMP2 is
located along the dendrites and gives characteristic punctate labeling (C). Double labeling with antibodies against synaptophysin (P38) (D) and VAMP2 (E)
indicates that VAMP2 is colocalized with the presynaptic marker (F). Double labeling for PSD-95 (G) and VAMP2 (H) shows partial colocalization
postsynaptic (I). Small, high-resolution pictures of single synapses from (F) and (I) are shown in the right part of these images, respectively. Scale bar: 20 μm.
doi:10.1371/journal.pone.0140868.g004
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6C). Contrary to our observations with GluA1, quantification showed only 41% GluA2/
VAMP2 double labeling of vesicles in postsynaptic spines, which was slightly less than in den-
dritic shafts, where 46% of the GluA2 gold particles were colocalized with VAMP2 (Fig 6D).
Vesicle immunoprecipitation experiments with GluA2 and VAMP2 antibodies gave similar
results to GluA1 and VAMP2, i.e. the two proteins co-immunoprecipitated. However, a crucial
difference was evident between the results with GluA1 and GluA2: While GluA1 is strongly
present in synaptic vesicles (Fig 6E and 6J), GluA2 is very weak in the same fraction (Fig 6G
and 6K). However, when we immunoprecipitate either VAMP2-positive or GluA2 positive ves-
icles from the vesicle fraction, the signal for GluA2 is clearly seen in the IP fraction (Fig 6G and
6K). Thus, contrary to GluA1, the concentration of GluA2 positive vesicles in postsynaptic
spines appears to be low, but the few GluA2 positive vesicles do also contain VAMP2 (Fig 6H),
as do the more numerous GluA1-positive synaptic vesicles. The levels of the two glutamate
receptor subunits are much more similar in whole brain homogenate (Fig 6E and 6G). Taken
together, these data indicate that GluA1 is abundant on VAMP2-positive vesicles in postsynap-
tic spines, relative to similar vesicles in dendrites, while GluA2-VAMP2-positive vesicles are
less common in spines and more evenly distributed between dendrites and spines. Control
experiments confirmed the presence of the synaptic vesicle marker synaptophysin in our vesi-
cle preparation (Fig 6L), but they were not contaminated by nonvesicular protein, i.e. they
were immunonegative for phosphate activated glutaminase [39] (Fig 6M), which is present in
high concentrations in synaptic mitochondria [40]. Electron micrographs of the vesicle
pellet also confirmed the purity of the preparation (Fig 6N).
Fig 5. Quantitation of synaptic VAMP2 immunogold labeling. (A) Schematic drawing showing regions of
interest in electron micrographs. PreCy: Presynaptic Cytoplasm. PreL: Presynaptic Lateral plasma
membrane. AZ: Active Zone. PoCy: Postsynaptic Cytoplasm. PoL: Postsynaptic Lateral membrane. PSD:
PostSynaptic Density. DCy: Dendrite Cytoplasm. DM: Dendritic plasmaMembrane. AM: Astrocyte plasma
Membrane. (B) Transverse histogram depicting the mean number of gold particles at every 30 nm distance
from the center of the synaptic cleft; negative values are postsynaptic, positive values are presynaptic. The
peak is about 200 nm from the center of the synaptic cleft, but significant levels are seen also in postsynaptic
cytoplasm. (C) Mean immunogold labeling over cytoplasmic regions of interest. (D) Mean immunogold
labeling over plasmamembrane regions of interest.
doi:10.1371/journal.pone.0140868.g005
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Fig 6. Vesicular colocalization of VAMP2 and AMPA receptor subunits. (A) Electron micrographs
showing double immunogold labeling of VAMP2 (10 nm gold particles) and GluA1 (20 nm gold) in spine and
dendrite. (B) Quantitative analysis of colocalization between VAMP2 and GluA1 in spines and dendrites. (C)
Electron micrographs showing double immunogold labeling of VAMP2 (10 nm gold particles) and GluA2 (20
nm gold particles). (D) Quantitative analysis of colocalization between VAMP2 and GluA2 in spines and
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VAMP2 facilitates differential vesicle trafficking of AMPA receptor
subunits
Having established the presence of GluA1 on VAMP2-containing vesicles in postsynaptic
spines, we wanted to investigate whether VAMP2 has a functional role in exocytotic insertion
of the glutamate receptor subunit into the synaptic plasma membrane. We performed immu-
nofluorescence staining of unpermeabilized, dissociated hippocampal cultures with an anti-
body against the N-terminal, external epitope of GluA1, before permeabilization and
subsequent immunostaining with an antibody against a somatodendritic protein, β-tubulin
(TuJ1) (Fig 7A). The neurons showed punctate GluA1 labeling (Fig 7A and 7B), corresponding
to synaptic sites where receptors have been inserted into the plasma membrane. Double label-
ing with GluA1 and PSD-95 gave almost fully overlapping punctate staining (Fig 7H–7J). Inter-
nal, cytoplasmic pools of the receptor were thus not stained. Similar labeling with anti-GluA2
(Fig 7C) did not give the typical punctate labeling pattern seen with GluA1, since the immuno-
fluorescence was drawn out through the dendrites, not confined merely to synaptic puncta,
corresponding to our previous observations at the immunogold and biochemical levels. Fig
7D–7G shows that preincubation of the two antibodies with their corresponding peptide anti-
gens abolished staining.
When cultures were treated overnight with tetanus toxin, which cleaves VAMP2 (Fig 8A
and 8B), confocal images showed significantly reduced (n = 1000 in both groups, p< 0.001,
independent samples T-test) labeling intensity of the GluA1 positive punctate structures (Fig
8C and 8D). Quantification of the maximum punctate labeling intensity showed that it was
reduced to about 63% upon treatment with tetanus toxin (Fig 8G). In conclusion, our data
strongly indicate that VAMP2 plays a role in insertion of the AMPA receptor subunit GluA1
into the synaptic plasma membrane.
Finally, we wanted to investigate if GluA2 is inserted by a similar VAMP2-dependent mech-
anism into the plasma membrane of postsynaptic spines. As noted above, the occurrence of
synaptic vesicles harboring both VAMP2 and GluA2 is more evenly distributed between den-
drites and spines than it is for GluA1. Tetanus toxin cleavage of VAMP2 was performed as
above, but now external epitopes of GluA2 were labeled instead of GluA1 (Fig 8E and 8F). Con-
trary to GluA1, the intensity of GluA2 labeling of synaptic puncta after tetanus toxin treatment
was slightly, but significantly, increased (n = 1000 in both groups, p< 0.001, independent sam-
ples T-test) (Fig 8H). Taken together, our data are compatible with a direct, regulated route for
VAMP2-dependent insertion of predominantly GluA1-containing AMPA receptors into the
plasma membrane in spines, both in the lateral postsynaptic membrane and directly in the syn-
aptic plasma membrane along the PSD. Contrary to this, we find indications for a more indi-
rect route for insertion of predominantly GluA2-containing AMPA receptors into the
dendritic plasma membrane. After insertion, GluA2-receptors may possibly migrate by mem-
brane diffusion into spines and the postsynaptic plasma membrane.
dendrites. (E–K) Immunoprecipitation (IP) of synaptic vesicles with magnetic beads coated with antibody,
along with brain homogenate (BH), synaptic vesicle (SV) preparations and flow-through (FT), all subjected to
gel electrophoresis and western blotting [65]. (E) IP with anti-GluA1, WB with anti-GluA1. (F) IP with anti-
GluA1, WB with anti-VAMP2. (G) IP with anti-GluA2, WB with anti-GluA2. (H) IP with anti-GluA2, WB with
anti-VAMP2. (I) IP with anti-VAMP2, WP with anti-VAMP2. (J) IP with anti-VAMP2, WB with anti-GluA1. (K)
IP with anti-VAMP2, WB with anti-GluA2. (L) WB of brain homogenate fractions stained with anti-
synaptophysin (P38) antibody. (M) WB of brain homogenate fractions stained with phosphate-activated
glutaminase [39] antibody. (N) Electron micrograph of vesicle preparation similar to the ones used in (E-M).
Scale bars: 100 nm (A spine, B), 125 nm (A dendrite), 100 nm (N).
doi:10.1371/journal.pone.0140868.g006
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Plasma membrane expression of AMPA receptor subunits after
presynaptic silencing with Bafilomycin
Treatment with tetanus toxin, however, will also inactivate VAMP2 in the presynaptic terminal,
and as a result reduce transmitter release. Blocking of vesicular refilling of glutamate with Bafilo-
mycin A1 was performed in cultures not treated with toxin to control for the effect of
Fig 7. Control immunolocalization of plasmamembrane AMPA receptor subunits (external epitopes)
in hippocampal neuronal cultures. (A) Beta-tubulin (green, anti-TuJ1) labeling of dendrite, after anti-GluA1
external epitope [66] labeling and subsequent plasmamembrane permeabilization. Note punctate GluA1 [66]
labeling along the dendrite. (B) Synaptophysin (P38, green) and GluA1 [66]. (C) Synaptophysin (green) and
GluA2 [66]. (D) Labeling with anti-GluA1. (E) Labeling with anti-GluA1, but the antibody was preincubated
with the peptide antigen before staining. (F) Labeling with anti-GluA2. (G) Labeling with anti-GluA2, but the
antibody was preincubated with the peptide antigen before staining. (H) Immunolabeling of non-
permeabilized neuronal cultures with ani-GluA1 (green). (I) Immunolabeling with the postsynaptic marker
anti-PSD95 [66] after permeabilization of neuronal cultures. (J) Merging of (H) and (I) showing postsynaptic
labeling of GluA1. Scale bar (in A, valid for all images): 10 μm.
doi:10.1371/journal.pone.0140868.g007
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presynaptic inactivity. Bafilomycin is a potent blocker of vacuolar ATPases [41] and inhibits
cross-membrane vesicular transport of neurotransmitter by inhibiting acidification of the vesi-
cles. We have previously shown that Bafilomycin A1 significantly decreases synaptic vesicular
release of glutamate in these hippocampal cultures [42]. Treatment of neuronal cultures with
Bafilomycin gave no significant reduction (n = 500 in both groups, p = 0.195, Mann-WhitneyU
test) in maximum punctate immunofluorescence intensity of GluA1 (Fig 9A, 9B and 9E). Thus,
in the present setup, presynaptic inactivity does not affect the plasma membrane expression of
GluA1. Bafilomycin inhibition of presynaptic release gave a slight, but significant decrease
(n = 500, p< 0.001, Mann-WhitneyU test) of surface GluA2 expression (Fig 9C, 9D and 9F).
Fig 8. Cleavage of VAMP2 with tetanus toxin disrupts synaptic insertion of GluA1, but not GluA2, in
the plasmamembrane of dissociated hippocampal cultures. (A and B) VAMP2 immunofluorescence
after permeabilization, in (B) also after tetanus toxin treatment. Note the effect of tetanus toxin, with disruption
of VAMP2. (C and D) Immunofluorescence against the external epitope of GluA1, in (D) also after tetanus
toxin treatment. (E and F) Immunofluorescence against the external epitope of GluA2, in (F) also after tetanus
treatment. (G) Graphical depiction of intensity of punctate, external GluA1 labeling, showing a significant
reduction of synaptic GluA1 after tetanus toxin treatment. (H) Graphical depiction of intensity of punctate,
external GluA2 labeling, showing a slight, but significant increase of synaptic GluA2 after tetanus toxin
treatment. Scale bar: 10 μm. Asterisks denote statistical significant difference (p < 0.001).
doi:10.1371/journal.pone.0140868.g008
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Discussion
In spite of a vast amount of research on the trafficking of glutamate receptors, we still do not
know the details of the molecular mechanisms for delivery of glutamate receptors to the post-
synaptic plasma membrane. The present investigation provides information on important
aspects of these mechanisms. First, we demonstrate the presence of small postsynaptic vesicles
and characterize their size and intrasynaptic localization. Second, we show that the SNARE
protein VAMP2 is associated with many of these vesicles, strongly substantiating the notion
that SNARE proteins regulate postsynaptic vesicle trafficking. Third, a significant proportion
of these postsynaptic vesicles harbor GluA1-containing AMPA receptors, and our results
strongly indicate that VAMP2 facilitates the insertion of these receptors into the postsynaptic
plasma membrane. Finally, our data indicate differential trafficking of GluA1 and GluA2 into
the spine plasma membrane, with GluA1 mostly taking a direct vesicular route from the spine
cytoplasm, while GluA2 may take an indirect route, being inserted into dendritic plasma mem-
brane before migrating to the synapse.
Our results rely heavily on antibody specificity and selectivity. We have controlled for these
factors in the different experiments, but acknowledge that, e.g. different sensitivities between
Fig 9. The effect on plasmamembrane expression of AMPA receptor subunits in hippocampal culture
after presynaptic silencing with Bafilomycin (BAF). (A) Control synapses immunolabeled with anti-GluA1
in non-permeabilized culture. (B) As in (A), but treated with Bafilomycin (BAF) before fixation. (C) Control
synapses immunolabeled with anti-GluA2 in non-permeabilized culture. (D) As in (C), but treated with
Bafilomycin (BAF) before fixation. (E) Quantification of difference in maximal punctate GluA1 labeling
intensities between control and Bafilomycin-treated cultures. There is no significant difference. (F)
Quantification of difference in maximal punctate GluA2 labeling intensities between control and Bafilomycin-
treated cultures. There is a slight, but significant decrease in labeling intensities after Bafilomycin treatment.
Asterisk denotes statistical significance (p < 0.001). Scale bar: 10 μm.
doi:10.1371/journal.pone.0140868.g009
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GluA1 and GluA2 antibodies may possibly influence our findings. Many of the VAMP2-la-
beled vesicles in our material show the immunogold particle close to the center of the vesicle,
inside the electron-lucent vesicle over the interior. This does not imply that the epitope is actu-
ally localized in the vesicular lumen. Because the epitope is bound to a complex of primary and
secondary antibodies coupled to a gold particle, the center of an immunogold particle can be
located up to 21 nm from the epitope. In the case of synaptic vesicle proteins like VAMP2, a
single immunogold particle is often attached by more than one primary antibody around the
circumference of the vesicle membrane, and it will thus be seen over the interior of the vesicle,
as is evident for other vesicle proteins as well [33, 43, 44].
Past research has provided indirect evidence for a vesicular pathway of local insertion of
AMPA receptors into the spine plasma membrane [6, 10, 11, 23–25]. The putative vesicles,
however, have never been demonstrated. When the SNARE complex and its function in pre-
synaptic vesicle exocytosis was first characterized [18], the existence of presynaptic vesicles in
the brain [45] and their exocytosis of transmitter [46, 47] had already been demonstrated.
With postsynaptic spines, the situation is different. We know that glutamate receptors migrate
from cytoplasmic stores to the postsynaptic plasma membrane [48]; indirect evidence, i.a. the
involvement of SNARE proteins [9, 11, 25, 48], support the notion that the receptors move to
the plasma membrane by exocytosis, but the organelles themselves have actually not been
shown. Thus, our ultrastructural demonstration of such vesicles within the postsynaptic cyto-
plasm (Fig 3) fills a gap in current knowledge about postsynaptic spine biology.
The proteins mediating the direct transfer from a postsynaptic spine cytoplasmic pool to a
plasma membrane pool are only just beginning to be determined. A strong indication of
SNARE complex involvement was provided by Kennedy and colleagues when they showed
that syntaxin-4 was involved with the exocytosis of AMPA receptors in dendritic spines [10].
Later, Jurado et al. [11] showed that the SNARE proteins syntaxin-3 and SNAP-47 are required
for regulated AMPA receptor exocytosis during LTP, but not for constitutive basal AMPA
receptor exocytosis. The same study showed that VAMP2 contributes to both regulated and
constitutive AMPA receptor exocytosis. Similarly, Araki and colleagues [49] showed that
VAMP2 is involved with insertion of GluA2-containing vesicles, but they did not differentiate
between dendritic shafts or spines.
Our results with electron microscopy, western blotting and co-immunoprecipitation take
this line of research further, showing that postsynaptic vesicles may harbor both VAMP2 and
GluA1 (Figs 3 and 6). Furthermore, by disrupting VAMP2 with tetanus toxin, we find evidence
that this SNARE protein is instrumental for exocytosis of GluA1-containing receptors in the
postsynaptic membrane. Tetanus toxin treatment, however, gave a small, but significant,
increase in synaptic concentrations of GluA2. This observation indicates that decreasing con-
centrations of synaptic GluA1-containing receptors may be replaced by lateral diffusion of
GluA2-containing receptors from a dendritic plasma membrane pool. As a control for silenc-
ing of inactive synapses, i.e. when we treat them with tetanus toxin, reducing their glutamate
release, we used Bafilomycin (Fig 9). Bafilomycin inhibits filling of presynaptic vesicles with
glutamate so that little glutamate is released from the axon terminals. This treatment did not
result in a reduction in surface expression of GluA1, as did the toxin. On the other hand, other
studies have shown that reducing transmitter release may cause an increase in surface expres-
sion of AMPA receptors in culture [50, 51]. This scaling effect, however, typically takes two or
three days to appear, much longer than our overnight treatment with Bafilomycin.
There are two interesting aspects of our observations that should be discussed: First,
VAMP2- and GluA1-labeled vesicles in many cases touched the spine plasma membrane, both
in perisynaptic areas as well as at the PSD, in addition to the many labeled vesicles within the
spine cytoplasm (Fig 3). This observation supports a direct route of insertion close to, or even
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directly into the plasma membrane corresponding to the PSD, as indicated by some investiga-
tions [10, 52, 53], but not by others [54, 55]. Secondly, we find indications that GluA1- and
GluA2-containing receptors may be differentially inserted into the plasma membrane. First of
all, they are affected differently by disrupting VAMP2 with tetanus toxin. Furthermore, blots
from synaptosomal vesicles are only very weakly GluA2-positive, while they are strong for
GluA1, but this difference is not evident in blots from whole brain homogenate (Fig 6E and
6G). This is supported by the electron microscopical observations that vesicles co-harboring
VAMP2 and GluA1 are abundant in spine cytoplasm compared to dendrites, while similar ves-
icles with VAMP2 and GluA2 are almost evenly distributed between dendritic shafts and spines
(Fig 6A–6D). Also, the confocal images of hippocampal, cultured neurons are in line with this,
showing GluA1 labeling in distinct puncta and GluA2 labeling along segments of dendrites
(Fig 7). While many researchers have favored insertion of fully assembled AMPA receptors
into the plasma membrane, e.g. in dendrites, our findings of differential localization and traf-
ficking of GluA1 and GluA2 indicate that exocytosis of AMPA receptor subunits may occur in
both spine and dendritic plasma membrane, respectively. Our results, then, are also compatible
with increasing evidence for differential trafficking of GluA1- and GluA2-containing receptors
[15, 16].
Our distinction between GluA1- and GluA2-containing AMPA receptors warrants some
discussion, as many AMPA receptors are believed to be heteromeric, containing both of these
subunits. Differential trafficking and insertion of AMPA receptors are of crucial importance to
synaptic plasticity and adaptation to different pathological or physiological conditions. In the
synapse, the GluA1/GluA2 heteromeric receptor is one of the major subunit compositions
[56]. Approximately 80% of synaptic and> 95% of somatic extrasynaptic receptors are
believed to be GluA1/A2 heteromers. However, in tissue extracts from the CA1 and CA2 areas
of the hippocampus, around 8% of the AMPA receptors were shown to be GluA1 homomers,
with a very small population of GluA1/GluA3 heteromers [57]. Furthermore, the molecular
composition of synaptic AMPA receptors can change in response to activity [58–60]. In sum-
mary, there is a need for elucidating the mechanisms for regulating the subunit composition of
synaptic AMPA receptors. Interpreted on the basis of previously published studies, our results
indicate that VAMP2 may facilitate vesicular insertion of GluA1-containing homomeric or
GluA2-lacking AMPA receptors into spines, while VAMP2 also could be involved with inser-
tion of GluA2-containing AMPA receptors into the dendritic plasma membrane before they
may migrate laterally to the spines.
There is also evidence that AMPA receptors may be stored in recycling endosomes [61]. In
our synapses, endosomic structures could sometimes be seen in spines, but they were not very
common. In synapses where recycling endosomes are important stores of AMPA receptors,
small vesicles could play a role in trafficking receptors to the plasma membrane and back.
Interestingly, work with another set of vesicle or endosomal trafficking proteins, Rab proteins,
also support trafficking of GluA1-containing endosomes into postsynaptic spines before inser-
tion into the postsynaptic plasma membrane [62]. Specifically, the authors found that Rab11--
dependent endosomes traffic GluA1-containing AMPA receptors from dendritic shafts into
spines. Subsequently, an additional endosomal trafficking step, controlled by Rab8, drives
receptor insertion into the synaptic membrane. In light of our own findings, which indicate
separate insertion routes for GluA1 homomeric/GluA2-lacking receptors and GluA2-contain-
ing receptors, it would have been very interesting to know whether other Rab proteins control
GluA2-containing AMPA receptors. Further work will show if our VAMP2/GluA1-positive
vesicles also harbor Rab8 or Rab11.
The two VAMP genes abundantly expressed in the brain are VAMP1 and VAMP2. The
protein detected in the hippocampal postsynaptic spines in the present study is very likely
Postsynaptic VAMP Facilitates Trafficking of AMPA Receptors
PLOS ONE | DOI:10.1371/journal.pone.0140868 October 21, 2015 19 / 24
VAMP2, as VAMP1 is expressed mainly in the spinal cord and only in low concentrations in
the hippocampus [27], and tetanus toxin only cleaves VAMP2, not VAMP1 [63]. Furthermore,
tetanus toxin does not cleave VAMP2 that is already assembled in a SNARE complex [38].
Thus, even after toxin treatment, there will be some insertion of GluA1 receptor subunits from
already docked vesicles.
In conclusion, our data show the presence of small, VAMP2-positive vesicles in postsynap-
tic hippocampal spines, colocalized with GluA1. Our results support a direct route of GluA1--
containing AMPA receptor insertion into the spine plasma membrane, while
GluA2-containing AMPA receptors are predominantly inserted into the dendritic plasma
membrane, supporting a lateral migration into the spine. In both cases, the insertion occurs by
VAMP2-mediated exocytosis of receptor-containing small vesicles. VAMP2 is well-known for
its facilitation of presynaptic vesicle exocytosis. But the two compartments, the presynaptic ter-
minal and the postsynaptic spine, are isolated by two plasma membranes from each other, so
the same SNARE proteins, in this case VAMP2, may easily function in the exocytosis of differ-
ent sets of vesicles, in different locations. As pointed out by Jurado et al. [11], however, differ-
ent sets of postsynaptic target SNAREs (syntaxins) may be involved with different types of
exocytosis, i.e. with regulated or constitutive exocytosis, respectively.
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